IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study


The purpose of this study is to assess HIV remission among HIV-infected neonates who initiate ART within 48 hours of birth. For purposes of this protocol, remission is defined as having no confirmed plasma HIV RNA>=LOD for 48 weeks following ART cessation. Additional aim for the study is to assess the safety of very early ART in neonates. Also, to evaluate immune activation and host and viral determinants, including maternal factors and HIV-specific immune responses, associated with HIV remission.


HIV-INFECTED, REMISSION, plasma, persistence, LPV exposures

Principal Investigator

Mobeen Rathore



Contact Information


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams